Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences (Nasdaq: NERV) will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026 at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Minerva Neurosciences (Nasdaq: NERV) will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026 at 8:30 AM ET.
Remy Luthringer, PhD, Executive Chairman & CEO, will deliver the company presentation; a replay will be available on the company’s Investors & Media Events and Presentations webpage for ninety days.
Details
News Market Reaction – NERV
On Mar 12, the day this news came out, NERV closed 5.34% above the previous close.
Data tracked by StockTitan Argus for the Mar 12 session.
Key Figures
- Shelf registration size
- $200,000,000
- S-3 shelf filed Mar 11, 2026
- Phase 3 sample size
- 380 patients
- Planned C19 roluperidone trial
- 2025 net loss
- $293.4 million
- GAAP net loss for 2025 per 10-K/8-K
- Accumulated deficit
- $688.8 million
- As of Dec 31, 2025
- Adjusted net loss
- $16.0 million
- Non-GAAP adjusted 2025 net loss
- Year-end cash
- $82.4 million
- Cash, equivalents and restricted cash at Dec 31, 2025
- Private placement proceeds
- $80.0 million
- Gross proceeds from Oct 2025 private placement
- Warrant potential proceeds
- $120.0 million
- Additional proceeds if Tranche A & B warrants fully exercised
Historical Context
-
Large 2025 GAAP loss and financing details weighed on shares.
-
Standard investor conference appearance had minimal price impact.
-
KOL event outlining Phase 3 design and unmet need supported a gain.
-
New director and funding plans for Phase 3 saw little price reaction.
-
Financing and FDA alignment for Phase 3 coincided with a price rise.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
central nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.
| The Stifel 2026 Virtual CNS Forum | |
| Format: | Company presentation |
| Day/Time: | Wednesday, March 18 at 8.30 AM ET |
| Webcast: | Webcast Link: |
| https://event.summitcast.com/view/4Ggc9Rmi4GQpDPGZwDp8g8/DdYPDYEQLLU6kp2AWRS6bu | |
If you are interested in a virtual meeting with the Minerva team during the conference, please reach out to your Stifel representative.
A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.